start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2008
dt-pub=20080325
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=神経性血圧調節に及ぼす高血糖および高インスリンの影響に関する循環薬理学的研究
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=1
ORCID=
affil-num=1
en-affil=
kn-affil=岡山大学
END
start-ver=1.4
cd-journal=joma
no-vol=58
cd-vols=
no-issue=10
article-no=
start-page=1445
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=20221013
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Polypharmacy in Older Adults with Alzheimer's Disease
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The number of patients with Alzheimer's disease is increasing annually. Most of these patients are older adults with comorbid physical illnesses, which means that they are often treated with a combination of medications for the disease they have and those for Alzheimer's disease. Thus, older adults with Alzheimer's disease are potentially at risk for polypharmacy. In addition, the drug interactions between Alzheimer's disease medications and those for the treatment of physical illnesses may reduce their efficacy and increase side effects. This article reviews polypharmacy and drug interactions in elderly patients with Alzheimer's disease, with a focus on psychotropic drugs.
en-copyright=
kn-copyright=
en-aut-name=EsumiSatoru
en-aut-sei=Esumi
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=UshioSoichiro
en-aut-sei=Ushio
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
affil-num=1
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=2
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=3
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
en-keyword=Alzheimer's disease
kn-keyword=Alzheimer's disease
en-keyword=polypharmacy
kn-keyword=polypharmacy
en-keyword=drug interactions
kn-keyword=drug interactions
END
start-ver=1.4
cd-journal=joma
no-vol=135
cd-vols=
no-issue=1
article-no=
start-page=39
end-page=42
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20230401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Drug interaction (56. Interaction among antiarrhythmic drugs and other drugs)
kn-title=薬物相互作用（56―抗不整脈薬の薬物相互作用）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
en-aut-name=MuraoTakuya
en-aut-sei=Murao
en-aut-mei=Takuya
kn-aut-name=村尾卓哉
kn-aut-sei=村尾
kn-aut-mei=卓哉
aut-affil-num=1
ORCID=
en-aut-name=EsumiSatoru
en-aut-sei=Esumi
en-aut-mei=Satoru
kn-aut-name=江角悟
kn-aut-sei=江角
kn-aut-mei=悟
aut-affil-num=2
ORCID=
en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=濱野裕章
kn-aut-sei=濱野
kn-aut-mei=裕章
aut-affil-num=3
ORCID=
en-aut-name=MurakawaKiminaka
en-aut-sei=Murakawa
en-aut-mei=Kiminaka
kn-aut-name=村川公央
kn-aut-sei=村川
kn-aut-mei=公央
aut-affil-num=4
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=5
ORCID=
affil-num=1
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=2
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=3
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=4
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=5
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
END
start-ver=1.4
cd-journal=joma
no-vol=134
cd-vols=
no-issue=2
article-no=
start-page=102
end-page=107
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=20220801
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Drug interaction (54. Drug interaction in the process of absorption and excretion of anticancer drugs)
kn-title=薬物相互作用（54―抗がん剤の吸収，排泄過程における薬物相互作用）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
en-aut-name=DanzakoMinato
en-aut-sei=Danzako
en-aut-mei=Minato
kn-aut-name=団迫湊
kn-aut-sei=団迫
kn-aut-mei=湊
aut-affil-num=1
ORCID=
en-aut-name=EsumiSatoru
en-aut-sei=Esumi
en-aut-mei=Satoru
kn-aut-name=江角悟
kn-aut-sei=江角
kn-aut-mei=悟
aut-affil-num=2
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=3
ORCID=
affil-num=1
en-affil=Department of pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=2
en-affil=Department of pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=3
en-affil=Department of pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
END
start-ver=1.4
cd-journal=joma
no-vol=134
cd-vols=
no-issue=3
article-no=
start-page=185
end-page=186
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=20221201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Drug interaction (55. Examples of drug interaction of great concern during pregnancy)
kn-title=薬物相互作用（55―妊婦において注意が必要な薬物相互作用の例）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
en-aut-name=ShiromizuShoya
en-aut-sei=Shiromizu
en-aut-mei=Shoya
kn-aut-name=白水翔也
kn-aut-sei=白水
kn-aut-mei=翔也
aut-affil-num=1
ORCID=
en-aut-name=EsumiSatoru
en-aut-sei=Esumi
en-aut-mei=Satoru
kn-aut-name=江角悟
kn-aut-sei=江角
kn-aut-mei=悟
aut-affil-num=2
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=3
ORCID=
affil-num=1
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=2
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=3
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
END
start-ver=1.4
cd-journal=joma
no-vol=22
cd-vols=
no-issue=8
article-no=
start-page=675
end-page=680
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=20220623
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Trends in places and causes of death among centenarians in Japan from 2006 to 2016
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aim
Amid the global aging, an establishment of healthcare policies for the aged population is a common issue to be addressed. However, few studies on centenarians have reported place and cause of death (PoD and CoD, respectively) as indicators of end-of-life care quality. This study aimed to analyze trends in PoD and CoD among centenarians in Japan.
Methods
Data from death certificates from Japanese vital statistics were analyzed; 205?513 deaths occurred among centenarians (aged ?100?years) in Japan during the period from 2006 to 2016. PoD prevalence was calculated for each CoD. Trends in PoD prevalence were analyzed using the Joinpoint regression model. Changing points, annual percentage changes, and average annual percentage changes (AAPCs) were calculated to examine trends.
Results
The number of deaths more than doubled from 10?340 in 2006 to 26?427 in 2016. PoDs were composed of hospitals (52.7%), nursing homes (31.4%), own homes (13.6%) and others (2.2%). Dementia and old age increased rapidly as CoD. Proportions of hospital and home deaths decreased, with AAPCs of ?2.3% (95% confidence interval [CI], ?2.6 to ?1.9) and ?2.3% (95% CI, ?3.2 to ?1.4), respectively. Conversely, the proportion of deaths in nursing homes rapidly increased, with an AAPC of 6.8% (95% CI, 6.0?7.7).
Conclusions
The results revealed changes in PoD among centenarians in Japan. Understanding these transitions is indispensable for health policy in aging societies.
en-copyright=
kn-copyright=
en-aut-name=KoyamaToshihiro
en-aut-sei=Koyama
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=HigashionnaTsukasa
en-aut-sei=Higashionna
en-aut-mei=Tsukasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=MaruoAkinori
en-aut-sei=Maruo
en-aut-mei=Akinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=UshioSoichiro
en-aut-sei=Ushio
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=HaradaKo
en-aut-sei=Harada
en-aut-mei=Ko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
affil-num=1
en-affil=Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=2
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=3
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=4
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=5
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=6
en-affil=Department of Medicine, Icahn School of Medicine at Mount Sinai
kn-affil=
affil-num=7
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=aging
kn-keyword=aging
en-keyword=centenarians
kn-keyword=centenarians
en-keyword=death
kn-keyword=death
en-keyword=nursing home
kn-keyword=nursing home
en-keyword=trend
kn-keyword=trend
END
start-ver=1.4
cd-journal=joma
no-vol=130
cd-vols=
no-issue=6
article-no=
start-page=833
end-page=840
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2010
dt-pub=20100601
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Ameliorative effect of propolis on insulin resistance in Otsuka Long-Evans Tokushima Fatty (OLETF) rats
kn-title=Propolis 長期投与による Otsuka Long-Evans Tokushima Fatty (OLETF) ラットの インスリン抵抗性改善作用
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Propolis is known to have abundant bioactive constituents and a variety of biological activities. To investigate the effect of Brazilian propolis on insulin resistance, 10-week-old Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a non-insulin-dependent type 2 diabetic model, were treated for 4 weeks with propolis (100 and 300 mg/kg, p.o.) or vehicle (control). Propolis treatment significantly decreased the plasma levels of insulin and insulin resistance index (Homeostasis Model Assessment-Insulin Resistance; HOM-IR), without affecting blood glucose levels and tended to lower systolic blood pressure compared with the control. In isolated and perfused mesenteric vascular beds of OLETF rats, propolis treatment resulted in significant reduction of sympathetic nerve-mediated vasoconstrictor response to periarterial nerve stimulation (PNS) and tended to increase calcitonin gene-related peptide (CGRP) nerve-mediated vasodilator response to PNS compared with in vehicle-treated OLETF rats. However, propolis treatment did not significantly affect the vasoconstrictor and vasodilator response to noradrenaline, CGRP, acetylcholine, and sodium nitroprusside. These results suggest that propolis could be an effective and functional food to prevent development of insulin resistance.
en-copyright=
kn-copyright=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=1
ORCID=
en-aut-name=FujiwaraHiroki
en-aut-sei=Fujiwara
en-aut-mei=Hiroki
kn-aut-name=藤原弘喜
kn-aut-sei=藤原
kn-aut-mei=弘喜
aut-affil-num=2
ORCID=
en-aut-name=HosodaMiho
en-aut-sei=Hosoda
en-aut-mei=Miho
kn-aut-name=細田美穂
kn-aut-sei=細田
kn-aut-mei=美穂
aut-affil-num=3
ORCID=
en-aut-name=HinoHayato
en-aut-sei=Hino
en-aut-mei=Hayato
kn-aut-name=日野隼人
kn-aut-sei=日野
kn-aut-mei=隼人
aut-affil-num=4
ORCID=
en-aut-name=HiraiKazuhiro
en-aut-sei=Hirai
en-aut-mei=Kazuhiro
kn-aut-name=平井和浩
kn-aut-sei=平井
kn-aut-mei=和浩
aut-affil-num=5
ORCID=
en-aut-name=OkamotoKazuaki
en-aut-sei=Okamoto
en-aut-mei=Kazuaki
kn-aut-name=岡本和明
kn-aut-sei=岡本
kn-aut-mei=和明
aut-affil-num=6
ORCID=
en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=金?
kn-aut-sei=金
kn-aut-mei=?
aut-affil-num=7
ORCID=
en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=高取真吾
kn-aut-sei=高取
kn-aut-mei=真吾
aut-affil-num=8
ORCID=
en-aut-name=
en-aut-sei=
en-aut-mei=
kn-aut-name=高木志真
kn-aut-sei=高木
kn-aut-mei=志真
aut-affil-num=9
ORCID=
en-aut-name=KawasakiHiromu
en-aut-sei=Kawasaki
en-aut-mei=Hiromu
kn-aut-name=川ｱ博己
kn-aut-sei=川ｱ
kn-aut-mei=博己
aut-affil-num=10
ORCID=
affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=2
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=5
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=6
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=7
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=8
en-affil=
kn-affil=日本新薬株式会社創薬研究所
affil-num=9
en-affil=
kn-affil=山田養蜂場本社研究開発部
affil-num=10
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
en-keyword=propolis
kn-keyword=propolis
en-keyword=insulin resistance
kn-keyword=insulin resistance
en-keyword=Otsuka Long-Evans Tokushima Fatty rat
kn-keyword=Otsuka Long-Evans Tokushima Fatty rat
en-keyword=periarterial nerve function
kn-keyword=periarterial nerve function
en-keyword=mesenteric vascular bed
kn-keyword=mesenteric vascular bed
END
start-ver=1.4
cd-journal=joma
no-vol=128
cd-vols=
no-issue=3
article-no=
start-page=419
end-page=424
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2008
dt-pub=20080301
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Effect of postprandial hyperglycemia and hyperinsulinemia on vascular responsiveness
kn-title=食後高血糖が血管反応性に及ぼす影響
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Recent clinical studies demonstrated that transient postprandial hyperglycemia and hyperinsulinemia may contribute to the development of hypertension. Therefore, we investigated influence of acute hyperglycemia and/or hyperinsulinemia induced by glucose or insulin infusion on neuronal and humoral control of vascular tone in rats. Euglycemic male Wistar rats were pithed under anesthesia and arterial blood pressure was measured. Changes in vascular responses to spinal cord stimulation (SCS) and intravenous bolus injections of noradrenaline, angiotensin II, calcitonin generelated peptide (CGRP), acetylcholine and sodium nitroprusside (SNP) were studied by infusing various concentration of glucose or insulin. Continuous glucose infusion, which increased both blood glucose and serum insulin levels, significantly augmented adrenergic nerve-mediated pressor responses to SCS without affecting injection of pressor responses to noradrenaline or angiotensin II. In pithed rats with artificially increased blood pressure and blockade of autonomic outflow, glucose infusion attenuated CGRPergic nerve-depressor responses to SCS without affecting depressor responses to injection of CGRP, acetylcholine or SNP. In pithed rats treated with octreotide, which increased blood glucose without increasing serum insulin levels, glucose infusion caused only significant augmentation of adrenergic nervemediated pressor responses. Combined infusion of insulin and glucose, which resulted in increased serum insulin levels with euglycemic, significantly augmented adrenergic nerve-mediated pressor responses and attenuated CGRPergic nerve-mediated depressor responses. The present results suggest that acute hyperglycemia and hyperinsulinemia increases adrenergic nerve-mediated vasoconstriction, which is partly associated with the blunted CGRPergic nerve function, and that plasma insulin concentration associated with hyperglycemia may be responsible for alteration of neuronal vascular regulation.
en-copyright=
kn-copyright=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=1
ORCID=
en-aut-name=TakatoriShingo
en-aut-sei=Takatori
en-aut-mei=Shingo
kn-aut-name=高取真吾
kn-aut-sei=高取
kn-aut-mei=真吾
aut-affil-num=2
ORCID=
en-aut-name=IwataniYukiko
en-aut-sei=Iwatani
en-aut-mei=Yukiko
kn-aut-name=岩谷有希子
kn-aut-sei=岩谷
kn-aut-mei=有希子
aut-affil-num=3
ORCID=
en-aut-name=YamawakiKosuke
en-aut-sei=Yamawaki
en-aut-mei=Kosuke
kn-aut-name=山脇康佑
kn-aut-sei=山脇
kn-aut-mei=康佑
aut-affil-num=4
ORCID=
en-aut-name=MiyashitaSatoko
en-aut-sei=Miyashita
en-aut-mei=Satoko
kn-aut-name=宮下智子
kn-aut-sei=宮下
kn-aut-mei=智子
aut-affil-num=5
ORCID=
en-aut-name=YabumaeNana
en-aut-sei=Yabumae
en-aut-mei=Nana
kn-aut-name=藪前奈々
kn-aut-sei=藪前
kn-aut-mei=奈々
aut-affil-num=6
ORCID=
en-aut-name=TakayamaFusako
en-aut-sei=Takayama
en-aut-mei=Fusako
kn-aut-name=高山房子
kn-aut-sei=高山
kn-aut-mei=房子
aut-affil-num=7
ORCID=
en-aut-name=MioMitsunobu
en-aut-sei=Mio
en-aut-mei=Mitsunobu
kn-aut-name=見尾光庸
kn-aut-sei=見尾
kn-aut-mei=光庸
aut-affil-num=8
ORCID=
en-aut-name=KawasakiHiromu
en-aut-sei=Kawasaki
en-aut-mei=Hiromu
kn-aut-name=川ｱ博己
kn-aut-sei=川ｱ
kn-aut-mei=博己
aut-affil-num=9
ORCID=
affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=2
en-affil=
kn-affil=日本新薬(株)創薬研究所
affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=5
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=6
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=7
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=8
en-affil=
kn-affil=就実大学薬学部薬効解析学分野
affil-num=9
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
en-keyword=hyperglycemia
kn-keyword=hyperglycemia
en-keyword=hyperinsulinemia
kn-keyword=hyperinsulinemia
en-keyword=Calcitonin gene-related peptide nerve
kn-keyword=Calcitonin gene-related peptide nerve
END
start-ver=1.4
cd-journal=joma
no-vol=127
cd-vols=
no-issue=12
article-no=
start-page=2065
end-page=2073
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2007
dt-pub=20071201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Effect of propolis on insulin resistance in fructose-drinking rats
kn-title=フルクトース負荷インスリン抵抗性モデル(ラット)におけるPropolisによるインスリン抵抗性改善作用
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Propolis, a honeybee product, contains a variety of biologically active substances. The present study was designed to investigate the effects of propolis on insulin resistance induced by fructose-drinking rats (FDR; type 2 diabetic animal model). Male Wistar rats (6 weeks old) received 15% fructose solution in drinking water for 8 weeks. FDR showed significant increases in plasma levels of insulin, Homeostasis Model Assessment ratio (HOMA-R, an index of insulin resistance), body weight, and systolic blood pressure but not blood glucose levels, when compared with control rats. Brazilian propolis extract (100 and 300mg/kg, p. o.) treatment for 8 weeks significantly decreased the plasma level of insulin, HOMA-R, and body weight, increased plasma triglyceride levels without affecting blood glucose and total cholesterol levels, and tended to decrease systolic blood pressure. In isolated and perfused mesenteric vascular beds of FDR, propolis treatment resulted in a significant reduction of sympathetic nerve-mediated vasoconstrictor response to periarterial nerve stimulation (PNS; 8Hz) and tended to increase the calcitonin gene-related peptide (CGRP) nerve-mediated vasodilator response to PNS, compared with those in untreated FDR. However, propolis treatment did not significantly affect norepinephrine-induced vasoconstriction and CGRP-induced vasodilation. These results suggest that propolis could be an effective functional food to prevent the development of insulin resistance.
en-copyright=
kn-copyright=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=1
ORCID=
en-aut-name=TakatoriShingo
en-aut-sei=Takatori
en-aut-mei=Shingo
kn-aut-name=高取真吾
kn-aut-sei=高取
kn-aut-mei=真吾
aut-affil-num=2
ORCID=
en-aut-name=KoayamaToshihiro
en-aut-sei=Koayama
en-aut-mei=Toshihiro
kn-aut-name=小山敏広
kn-aut-sei=小山
kn-aut-mei=敏広
aut-affil-num=3
ORCID=
en-aut-name=GodaMitsuhiro
en-aut-sei=Goda
en-aut-mei=Mitsuhiro
kn-aut-name=合田光寛
kn-aut-sei=合田
kn-aut-mei=光寛
aut-affil-num=4
ORCID=
en-aut-name=IwataniYukiko
en-aut-sei=Iwatani
en-aut-mei=Yukiko
kn-aut-name=岩谷有希子
kn-aut-sei=岩谷
kn-aut-mei=有希子
aut-affil-num=5
ORCID=
en-aut-name=DoiShima
en-aut-sei=Doi
en-aut-mei=Shima
kn-aut-name=土井志真
kn-aut-sei=土井
kn-aut-mei=志真
aut-affil-num=6
ORCID=
en-aut-name=KawasakiHiromu
en-aut-sei=Kawasaki
en-aut-mei=Hiromu
kn-aut-name=川ｱ博己
kn-aut-sei=川ｱ
kn-aut-mei=博己
aut-affil-num=7
ORCID=
affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=2
en-affil=
kn-affil=日本新薬創薬研究所
affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=5
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=6
en-affil=
kn-affil=山田養蜂場本社研究開発部
affil-num=7
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
en-keyword=propolis
kn-keyword=propolis
en-keyword=fructose-drinking rat
kn-keyword=fructose-drinking rat
en-keyword=insulin resistance
kn-keyword=insulin resistance
en-keyword=periarterial nerve function
kn-keyword=periarterial nerve function
END
start-ver=1.4
cd-journal=joma
no-vol=31
cd-vols=
no-issue=11
article-no=
start-page=2103
end-page=2107
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2008
dt-pub=20081101
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Royal jelly ameliorates insulin resistance in fructose-drinking rats
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Royal jelly (RJ) is known to contain excellent nutrition and a variety of biological activities. The present study was designed to investigate the effects of RJ on insulin resistance (hyperinsulinemia) in fructose-drinking rats (FDR; insulin resistance animal model). Male Wistar rats (6 weeks old) received 15% fructose solution in drinking water for 8 weeks. FDR showed significant increases in plasma levels of insulin and triglyceride, Homeostasis Model Assessment ratio (HOMA-R, an index of insulin resistance), and systolic blood pressure, but not blood glucose levels, when compared with control rats. RJ (100, 300mg/kg, p.o.) treatment for 8 weeks significantly decreased the plasma levels of insulin and triglyceride, HOMA-R, without affecting blood glucose or total cholesterol levels and tended to lower systolic blood pressure. In isolated and perfused mesenteric vascular beds of FDR, RJ treatment resulted in a significant reduction in sympathetic nerve-mediated vasoconstrictor response to periarterial nerve stimulation (PNS) and tended to increase the calcitonin gene-related peptide (CGRP) nervemediated vasodilator response to PNS, compared with those in untreated FDR. However, RJ treatment did not significantly affect norepinephrine-induced vasoconstriction or CGRP-induced vasodilation. These results suggest that RJ could be an effective functional food to prevent insulin resistance associated with the development of hypertension.
en-copyright=
kn-copyright=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=1
ORCID=
en-aut-name=TakatoriShingo
en-aut-sei=Takatori
en-aut-mei=Shingo
kn-aut-name=高取真吾
kn-aut-sei=高取
kn-aut-mei=真吾
aut-affil-num=2
ORCID=
en-aut-name=GodaMitsuhiro
en-aut-sei=Goda
en-aut-mei=Mitsuhiro
kn-aut-name=合田光寛
kn-aut-sei=合田
kn-aut-mei=光寛
aut-affil-num=3
ORCID=
en-aut-name=KoyamaToshihiro
en-aut-sei=Koyama
en-aut-mei=Toshihiro
kn-aut-name=小山敏広
kn-aut-sei=小山
kn-aut-mei=敏広
aut-affil-num=4
ORCID=
en-aut-name=IwataniYukiko
en-aut-sei=Iwatani
en-aut-mei=Yukiko
kn-aut-name=岩谷有希子
kn-aut-sei=岩谷
kn-aut-mei=有希子
aut-affil-num=5
ORCID=
en-aut-name=JinXin
en-aut-sei=Jin
en-aut-mei=Xin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=Takada-DoiShima
en-aut-sei=Takada-Doi
en-aut-mei=Shima
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=KawasakiHiromu
en-aut-sei=Kawasaki
en-aut-mei=Hiromu
kn-aut-name=川ｱ博己
kn-aut-sei=川ｱ
kn-aut-mei=博己
aut-affil-num=8
ORCID=
affil-num=1
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=2
en-affil=
kn-affil=日本新薬創薬研究所
affil-num=3
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=4
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=5
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=6
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
affil-num=7
en-affil=
kn-affil=山田養蜂場本社研究開発部
affil-num=8
en-affil=
kn-affil=岡山大学大学院医歯薬学総合研究科臨床薬学分野
en-keyword=royal jelly
kn-keyword=royal jelly
en-keyword=fructose-drinking rat
kn-keyword=fructose-drinking rat
en-keyword=insulin resistance
kn-keyword=insulin resistance
en-keyword=periarterial nerve function
kn-keyword=periarterial nerve function
END
start-ver=1.4
cd-journal=joma
no-vol=29
cd-vols=
no-issue=4
article-no=
start-page=1027
end-page=1033
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2014
dt-pub=2014
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Utility of simple suspension method compared to loss of drug using crushing method on tube administration
kn-title=粉砕法による経管投与における薬剤量損失に対する簡易懸濁法の有用性についての検討
en-subtitle=
kn-subtitle=
en-abstract=Objective: In the past, a conventional crushing method was used for the administration of tablets or capsules by tube in patients with dysphagia. However, this method has several problems, such as a loss of the drug amount and tube clogging. Recently, tube administration by a simple suspension method was developed to solve these problems in the conventional crushing method.
Methods: In the present study, we investigated to what extent the dosage amount is lost using the simple suspension method compared to crushing method, employing 5 drugs which are frequently administered by tube in Okayama University Hospital.
Results: Drug weights of the 5 agents decreased by 70 〜 90% in the grinding and packaging processes because of drug adhesion to the mortar, packaging machine, and drug package paper. The suspension of all drugs using the simple suspension method was uniform, while only the suspension of Warfarin? ground using the crushing method was shown to be showed inhomogeneous, which is expected to lead to a loss of drug. The drug content on assuming clinical a setting after tube passage was compared between the two methods. The recovery of warfarin?, characterized as unstable using the crushing method, was nearly 50%, but loss was prevented by 80% with the use of bags of medicine. For the simple suspension method, the recovery of warfarin? was almost 100%.
Conclusion: The results of this study suggest that the simple suspension method is particularly effective for the tube administration of drugs characterized as unstable.
kn-abstract=【目的】従来の薬剤経管投与法である粉砕法は薬効の減少につながる薬剤量の損失が指摘されている。そこで粉砕法による薬剤量損失に対する簡易懸濁法の有用性について検討した。
【方法】頻繁に粉砕指示がなされる5種類の薬剤を用いて粉砕・分包による薬物含量減少、薬剤調製時の懸濁性および実際の経管投与を想定した薬物含量について2つの方法を比較した。
【結果】薬剤を粉砕・分包するとそれぞれの薬物含量は減少した。またワーファリン?錠を粉砕して水に溶解すると完全には懸濁せず、小さな塊が生じたが、簡易懸濁法では均一に懸濁した。ワーファリン?錠の経管投与を想定した実験において粉砕法では薬物含量が大幅に減少したが、簡易懸濁法では、ほとんど損失が認められなかった。【結論】簡易懸濁法は粉砕法に比べて薬剤損失の面で有用性が高いことが示唆され、ワーファリン?錠のように安定性が悪い薬剤では特に適正な薬物投与に貢献出来ると考えられる。
en-copyright=
kn-copyright=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=1
ORCID=
en-aut-name=KoyamaToshihiro
en-aut-sei=Koyama
en-aut-mei=Toshihiro
kn-aut-name=小山敏広
kn-aut-sei=小山
kn-aut-mei=敏広
aut-affil-num=2
ORCID=
en-aut-name=AibaTetsuya
en-aut-sei=Aiba
en-aut-mei=Tetsuya
kn-aut-name=合葉哲也
kn-aut-sei=合葉
kn-aut-mei=哲也
aut-affil-num=3
ORCID=
en-aut-name=AmanoManabu
en-aut-sei=Amano
en-aut-mei=Manabu
kn-aut-name=天野学
kn-aut-sei=天野
kn-aut-mei=学
aut-affil-num=4
ORCID=
en-aut-name=AndoTetsuaki
en-aut-sei=Ando
en-aut-mei=Tetsuaki
kn-aut-name=安藤哲信
kn-aut-sei=安藤
kn-aut-mei=哲信
aut-affil-num=5
ORCID=
en-aut-name=KurataNaomi
en-aut-sei=Kurata
en-aut-mei=Naomi
kn-aut-name=倉田なおみ
kn-aut-sei=倉田
kn-aut-mei=なおみ
aut-affil-num=6
ORCID=
en-aut-name=NawaHideki
en-aut-sei=Nawa
en-aut-mei=Hideki
kn-aut-name=名和秀起
kn-aut-sei=名和
kn-aut-mei=秀起
aut-affil-num=7
ORCID=
en-aut-name=NakuraHironori
en-aut-sei=Nakura
en-aut-mei=Hironori
kn-aut-name=名倉弘哲
kn-aut-sei=名倉
kn-aut-mei=弘哲
aut-affil-num=8
ORCID=
en-aut-name=KitamuraYoshihisa
en-aut-sei=Kitamura
en-aut-mei=Yoshihisa
kn-aut-name=北村佳久
kn-aut-sei=北村
kn-aut-mei=佳久
aut-affil-num=9
ORCID=
en-aut-name=SendoToshiaki
en-aut-sei=Sendo
en-aut-mei=Toshiaki
kn-aut-name=千堂年昭
kn-aut-sei=千堂
kn-aut-mei=年昭
aut-affil-num=10
ORCID=
affil-num=1
en-affil=
kn-affil=岡山大学大学院 医歯薬学総合研究科
affil-num=2
en-affil=
kn-affil=岡山大学大学院 医歯薬学総合研究科
affil-num=3
en-affil=
kn-affil=岡山大学大学院 医歯薬学総合研究科
affil-num=4
en-affil=
kn-affil=兵庫医療大学 薬学部
affil-num=5
en-affil=
kn-affil=吉備高原ルミエール病院 薬剤科
affil-num=6
en-affil=
kn-affil=昭和大学 薬学部
affil-num=7
en-affil=
kn-affil=岡山大学病院 薬剤部
affil-num=8
en-affil=
kn-affil=岡山大学大学院 医歯薬学総合研究科
affil-num=9
en-affil=
kn-affil=岡山大学病院 薬剤部
affil-num=10
en-affil=
kn-affil=岡山大学病院 薬剤部
en-keyword=簡易懸濁法 (simple suspension method)
kn-keyword=簡易懸濁法 (simple suspension method)
en-keyword=経管投与 (tube administration)
kn-keyword=経管投与 (tube administration)
en-keyword=薬剤量の損失 (loss of drug amount)
kn-keyword=薬剤量の損失 (loss of drug amount)
END
start-ver=1.4
cd-journal=joma
no-vol=135
cd-vols=
no-issue=2
article-no=
start-page=89
end-page=91
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20230801
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Drug interaction (57. Drug interactions in renal failure)
kn-title=薬物相互作用（57―腎不全の薬物相互作用）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=濱野裕章
kn-aut-sei=濱野
kn-aut-mei=裕章
aut-affil-num=1
ORCID=
en-aut-name=KajizonoMakoto
en-aut-sei=Kajizono
en-aut-mei=Makoto
kn-aut-name=鍛治園誠
kn-aut-sei=鍛治園
kn-aut-mei=誠
aut-affil-num=2
ORCID=
en-aut-name=NishiharaShigeki
en-aut-sei=Nishihara
en-aut-mei=Shigeki
kn-aut-name=西原茂樹
kn-aut-sei=西原
kn-aut-mei=茂樹
aut-affil-num=3
ORCID=
en-aut-name=MurakawaKiminaka
en-aut-sei=Murakawa
en-aut-mei=Kiminaka
kn-aut-name=村川公央
kn-aut-sei=村川
kn-aut-mei=公央
aut-affil-num=4
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=5
ORCID=
affil-num=1
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=2
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=3
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=4
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=5
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
END
start-ver=1.4
cd-journal=joma
no-vol=478
cd-vols=
no-issue=8
article-no=
start-page=1779
end-page=1790
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=20221226
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Significance of UGT1A6, UGT1A9, and UGT2B7 genetic variants and their mRNA expression in the clinical outcome of renal cell carcinoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=UDP-glucuronosyltransferase (UGT) metabolizes a number of endogenous and exogenous substrates. Renal cells express high amounts of UGT; however, the significance of UGT in patients with renal cell carcinoma (RCC) remains unknown. In this study, we profile the mRNA expression of UGT subtypes (UGT1A6, UGT1A9, and UGT2B7) and their genetic variants in the kidney tissue of 125 Japanese patients with RCC (Okayama University Hospital, Japan). In addition, we elucidate the association between the UGT variants and UGT mRNA expression levels and clinical outcomes in these patients. The three representative genetic variants, namely, UGT1A6 541A > G, UGT1A9 i399C > T, and UGT2B7-161C > T, were genotyped, and their mRNA expression levels in each tissue were determined. We found that the mRNA expression of the three UGTs (UGT1A6, UGT1A9, and UGT2B7) are significantly downregulated in RCC tissues. Moreover, in patients with RCC, the UGT2B7-161C > T variant and high UGT2B7 mRNA expression are significantly correlated with preferable cancer-specific survival (CSS) and overall survival (OS), respectively. As such, the UGT2B7-161C > T variant and UGT2B7 mRNA expression level were identified as significant independent prognostic factors of CSS and CSS/OS, respectively. Taken together, these findings indicate that UGT2B7 has a role in RCC progression and may, therefore, represent a potential prognostic biomarker for patients with RCC.
en-copyright=
kn-copyright=
en-aut-name=MatsumotoJun
en-aut-sei=Matsumoto
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=NishimotoAnzu
en-aut-sei=Nishimoto
en-aut-mei=Anzu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=WatariShogo
en-aut-sei=Watari
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=UekiHideo
en-aut-sei=Ueki
en-aut-mei=Hideo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=ShiromizuShoya
en-aut-sei=Shiromizu
en-aut-mei=Shoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=IwataNaohiro
en-aut-sei=Iwata
en-aut-mei=Naohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=TakedaTatsuaki
en-aut-sei=Takeda
en-aut-mei=Tatsuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=UshioSoichiro
en-aut-sei=Ushio
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=KajizonoMakoto
en-aut-sei=Kajizono
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=FujiyoshiMasachika
en-aut-sei=Fujiyoshi
en-aut-mei=Masachika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=KoyamaToshihiro
en-aut-sei=Koyama
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=WadaKoichiro
en-aut-sei=Wada
en-aut-mei=Koichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=
en-aut-name=NasuYasutomo
en-aut-sei=Nasu
en-aut-mei=Yasutomo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=
en-aut-name=AriyoshiNoritaka
en-aut-sei=Ariyoshi
en-aut-mei=Noritaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=
affil-num=1
en-affil=Department of Personalized Medicine and Preventive Healthcare Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=2
en-affil=Department of Personalized Medicine and Preventive Healthcare Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=3
en-affil=Department of Urology, National Hospital Organization Okayama Medical Center
kn-affil=
affil-num=4
en-affil=Department of Urology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=5
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=6
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=7
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=8
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=9
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=10
en-affil=Department of Pharmacy, Tottori University Hospital
kn-affil=
affil-num=11
en-affil=Department of Pharmaceuticals Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=12
en-affil=Department of Urology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=13
en-affil=Department of Urology, Faculty of Medicine, Shimane University
kn-affil=
affil-num=14
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=15
en-affil=Department of Urology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=16
en-affil=Department of Personalized Medicine and Preventive Healthcare Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=Genetic variant
kn-keyword=Genetic variant
en-keyword=Polymorphism
kn-keyword=Polymorphism
en-keyword=Renal cell carcinoma
kn-keyword=Renal cell carcinoma
en-keyword=Survival
kn-keyword=Survival
en-keyword=UDP-glucuronosyltransferase
kn-keyword=UDP-glucuronosyltransferase
END
start-ver=1.4
cd-journal=joma
no-vol=135
cd-vols=
no-issue=3
article-no=
start-page=167
end-page=171
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20231201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Drug interaction (58. Drug interactions in tacrolimus)
kn-title=薬物相互作用（58―タクロリムスの薬物相互作用）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
en-aut-name=KimuraIkuya
en-aut-sei=Kimura
en-aut-mei=Ikuya
kn-aut-name=木村郁哉
kn-aut-sei=木村
kn-aut-mei=郁哉
aut-affil-num=1
ORCID=
en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=濱野裕章
kn-aut-sei=濱野
kn-aut-mei=裕章
aut-affil-num=2
ORCID=
en-aut-name=KajizonoMakoto
en-aut-sei=Kajizono
en-aut-mei=Makoto
kn-aut-name=鍛治園誠
kn-aut-sei=鍛治園
kn-aut-mei=誠
aut-affil-num=3
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=4
ORCID=
affil-num=1
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=2
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=3
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=4
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
END
start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=6
article-no=
start-page=595
end-page=605
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202312
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Concomitant Use of Multiple Nephrotoxins including Renal Hypoperfusion Medications Causes Vancomycin-Associated Nephrotoxicity: Combined Retrospective Analyses of Two Real-World Databases
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=There is a growing concern about the relationship between vancomycin-associated nephrotoxicity (VAN) and concomitant use of nephrotoxins. We examined this relationship by combined retrospective analyses of two real-world databases. Initially, the FDA Adverse Event Reporting System (FAERS) was analyzed for the effects of concomitant use of one or more nephrotoxins on VAN and the types of combinations of nephrotoxins that exacerbate VAN. Next, electronic medical records (EMRs) of patients who received vancomycin (VCM) at Tokushima University Hospital between January 2006 and March 2019 were examined to confirm the FAERS analysis. An elevated reporting odds ratio (ROR) was observed with increases in the number of nephrotoxins administered (VCM + one nephrotoxin, adjusted ROR (95% confidence interval [CI]) 1.67 [1.51-1.85]; VCM + ?2 nephrotoxins, adjusted ROR [95% CI] 1.54 [1.37-1.73]) in FAERS. EMRs analysis showed that the number of nephrotoxins was associated with higher incidences of VAN [odds ratio: 1.99; 95% CI: 1.42-2.78]. Overall, concomitant use of nephrotoxins was associated with an increased incidence of VAN, especially when at least one of those nephrotoxins was a renal hypoperfusion medication (furosemide, non-steroidal anti-inflammatory drugs, and vasopressors). The concomitant use of multiple nephrotoxins, especially including renal hypoperfusion medication, should be avoided to prevent VAN.
en-copyright=
kn-copyright=
en-aut-name=BandoTakashi
en-aut-sei=Bando
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=ChumaMasayuki
en-aut-sei=Chuma
en-aut-mei=Masayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=NiimuraTakahiro
en-aut-sei=Niimura
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=OkadaNaoto
en-aut-sei=Okada
en-aut-mei=Naoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=KondoMasateru
en-aut-sei=Kondo
en-aut-mei=Masateru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=IzumiYuki
en-aut-sei=Izumi
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=IshidaShunsuke
en-aut-sei=Ishida
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=YoshiokaToshihiko
en-aut-sei=Yoshioka
en-aut-mei=Toshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=AsadaMizuho
en-aut-sei=Asada
en-aut-mei=Mizuho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=TakechiKenshi
en-aut-sei=Takechi
en-aut-mei=Kenshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=GodaMitsuhiro
en-aut-sei=Goda
en-aut-mei=Mitsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
en-aut-name=MiyataKoji
en-aut-sei=Miyata
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=
en-aut-name=YagiKenta
en-aut-sei=Yagi
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=
en-aut-name=Izawa-IshizawaYuki
en-aut-sei=Izawa-Ishizawa
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=
en-aut-name=AzumaMomoyo
en-aut-sei=Azuma
en-aut-mei=Momoyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=
en-aut-name=YanagawaHiroaki
en-aut-sei=Yanagawa
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=
en-aut-name=TasakiYoshikazu
en-aut-sei=Tasaki
en-aut-mei=Yoshikazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=
en-aut-name=IshizawaKeisuke
en-aut-sei=Ishizawa
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=
affil-num=1
en-affil=Department of Pharmacy, Tokushima University Hospital
kn-affil=
affil-num=2
en-affil=Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital
kn-affil=
affil-num=3
en-affil=Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences
kn-affil=
affil-num=4
en-affil=Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital
kn-affil=
affil-num=5
en-affil=Department of Pharmacy, Tokushima University Hospital
kn-affil=
affil-num=6
en-affil=Department of Pharmacy, Tokushima University Hospital
kn-affil=
affil-num=7
en-affil=Department of Pharmacy, Tokushima University Hospital
kn-affil=
affil-num=8
en-affil=Department of Pharmacy, Tokushima University Hospital
kn-affil=
affil-num=9
en-affil=Department of Pharmacy, Tokushima University Hospital
kn-affil=
affil-num=10
en-affil=Department of Medical Molecular Informatics, Meiji Pharmaceutical University
kn-affil=
affil-num=11
en-affil=Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences
kn-affil=
affil-num=12
en-affil=Department of Drug Information Analysis, College of Pharmaceutical Sciences, Matsuyama University
kn-affil=
affil-num=13
en-affil=Department of Pharmacy, Tokushima University Hospital
kn-affil=
affil-num=14
en-affil=Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences
kn-affil=
affil-num=15
en-affil=Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital
kn-affil=
affil-num=16
en-affil=Department of Pharmacology, Tokushima University Graduate School of Biomedical Sciences
kn-affil=
affil-num=17
en-affil=Department of Infection Control and Prevention, Tokushima University Hospital
kn-affil=
affil-num=18
en-affil=Department of Nursing, Faculty of Health and Welfare, Tokushima Bunri University
kn-affil=
affil-num=19
en-affil=Department of Hospital Pharmacy and Pharmacology, Asahikawa Medical University
kn-affil=
affil-num=20
en-affil=Department of Pharmacy, Tokushima University Hospital
kn-affil=
en-keyword=vancomycin-associated nephrotoxicity
kn-keyword=vancomycin-associated nephrotoxicity
en-keyword=polypharmacy
kn-keyword=polypharmacy
en-keyword=nephrotoxin
kn-keyword=nephrotoxin
en-keyword=spontaneous adverse event reporting database
kn-keyword=spontaneous adverse event reporting database
en-keyword=electronic medical records
kn-keyword=electronic medical records
END
start-ver=1.4
cd-journal=joma
no-vol=136
cd-vols=
no-issue=2
article-no=
start-page=83
end-page=84
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240801
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=mRNA-vaccine
kn-title=mRNA ワクチン
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
en-aut-name=TanakaYuta
en-aut-sei=Tanaka
en-aut-mei=Yuta
kn-aut-name=田中雄太
kn-aut-sei=田中
kn-aut-mei=雄太
aut-affil-num=1
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=2
ORCID=
affil-num=1
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=2
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
END
start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=
article-no=
start-page=1371342
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240326
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Lysyl oxidase-like 4 promotes the invasiveness of triple-negative breast cancer cells by orchestrating the invasive machinery formed by annexin A2 and S100A11 on the cell surface
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Our earlier research revealed that the secreted lysyl oxidase-like 4 (LOXL4) that is highly elevated in triple-negative breast cancer (TNBC) acts as a catalyst to lock annexin A2 on the cell membrane surface, which accelerates invasive outgrowth of the cancer through the binding of integrin-β1 on the cell surface. However, whether this machinery is subject to the LOXL4-mediated intrusive regulation remains uncertain.
Methods: Cell invasion was assessed using a transwell-based assay, protein?protein interactions by an immunoprecipitation?Western blotting technique and immunocytochemistry, and plasmin activity in the cell membrane by gelatin zymography.
Results: We revealed that cell surface annexin A2 acts as a receptor of plasminogen via interaction with S100A10, a key cell surface annexin A2-binding factor, and S100A11. We found that the cell surface annexin A2/S100A11 complex leads to mature active plasmin from bound plasminogen, which actively stimulates gelatin digestion, followed by increased invasion.
Conclusion: We have refined our understanding of the role of LOXL4 in TNBC cell invasion: namely, LOXL4 mediates the upregulation of annexin A2 at the cell surface, the upregulated annexin 2 binds S100A11 and S100A10, and the resulting annexin A2/S100A11 complex acts as a receptor of plasminogen, readily converting it into active-form plasmin and thereby enhancing invasion.
en-copyright=
kn-copyright=
en-aut-name=TakahashiTetta
en-aut-sei=Takahashi
en-aut-mei=Tetta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=TomonobuNahoko
en-aut-sei=Tomonobu
en-aut-mei=Nahoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=KinoshitaRie
en-aut-sei=Kinoshita
en-aut-mei=Rie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=YamamotoKen-Ichi
en-aut-sei=Yamamoto
en-aut-mei=Ken-Ichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=MurataHitoshi
en-aut-sei=Murata
en-aut-mei=Hitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=KomalasariNi Luh Gede Yoni
en-aut-sei=Komalasari
en-aut-mei=Ni Luh Gede Yoni
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=ChenYouyi
en-aut-sei=Chen
en-aut-mei=Youyi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=JiangFan
en-aut-sei=Jiang
en-aut-mei=Fan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=GoharaYuma
en-aut-sei=Gohara
en-aut-mei=Yuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
en-aut-name=OchiToshiki
en-aut-sei=Ochi
en-aut-mei=Toshiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=
en-aut-name=RumaI. Made Winarsa
en-aut-sei=Ruma
en-aut-mei=I. Made Winarsa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=
en-aut-name=SumardikaI. Wayan
en-aut-sei=Sumardika
en-aut-mei=I. Wayan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=
en-aut-name=ZhouJin
en-aut-sei=Zhou
en-aut-mei=Jin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=
en-aut-name=HonjoTomoko
en-aut-sei=Honjo
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=
en-aut-name=SakaguchiYoshihiko
en-aut-sei=Sakaguchi
en-aut-mei=Yoshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=
en-aut-name=YamauchiAkira
en-aut-sei=Yamauchi
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=
en-aut-name=KuribayashiFutoshi
en-aut-sei=Kuribayashi
en-aut-mei=Futoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=
en-aut-name=KondoEisaku
en-aut-sei=Kondo
en-aut-mei=Eisaku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=
en-aut-name=InoueYusuke
en-aut-sei=Inoue
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=
en-aut-name=FutamiJunichiro
en-aut-sei=Futami
en-aut-mei=Junichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=
en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=
en-aut-name=SakaguchiMasakiyo
en-aut-sei=Sakaguchi
en-aut-mei=Masakiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=
affil-num=1
en-affil=Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=2
en-affil=Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=3
en-affil=Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=4
en-affil=Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=5
en-affil=Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=6
en-affil=Faculty of Medicine, Udayana University
kn-affil=
affil-num=7
en-affil=Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine
kn-affil=
affil-num=8
en-affil=Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=9
en-affil=Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=10
en-affil=Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=11
en-affil=Faculty of Medicine, Udayana University
kn-affil=
affil-num=12
en-affil=Faculty of Medicine, Udayana University
kn-affil=
affil-num=13
en-affil=Medical Oncology Department of Gastrointestinal Tumors, Liaoning Cancer Hospital & Institute, Cancer Hospital of the Dalian University of Technology
kn-affil=
affil-num=14
en-affil=Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=
affil-num=15
en-affil=Department of Microbiology, Tokushima Bunri University
kn-affil=
affil-num=16
en-affil=Department of Biochemistry, Kawasaki Medical School
kn-affil=
affil-num=17
en-affil=Department of Biochemistry, Kawasaki Medical School
kn-affil=
affil-num=18
en-affil=Division of Tumor Pathology, Near InfraRed Photo-Immuno-Therapy Research Institute, Kansai Medical University
kn-affil=
affil-num=19
en-affil=Faculty of Science and Technology, Division of Molecular Science, Gunma University
kn-affil=
affil-num=20
en-affil=Department of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=
affil-num=21
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=22
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=23
en-affil=Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=lysyl oxidase
kn-keyword=lysyl oxidase
en-keyword=annexin A2
kn-keyword=annexin A2
en-keyword=S100A11
kn-keyword=S100A11
en-keyword=plasmin
kn-keyword=plasmin
en-keyword=cancer microenvironment
kn-keyword=cancer microenvironment
END
start-ver=1.4
cd-journal=joma
no-vol=136
cd-vols=
no-issue=1
article-no=
start-page=29
end-page=32
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Drug interaction (59. Drug interaction of molecular targeted therapies for rare lung cancer)
kn-title=薬物相互作用（59―肺癌希少フラクションの分子標的治療薬）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
en-aut-name=OkudaHiroto
en-aut-sei=Okuda
en-aut-mei=Hiroto
kn-aut-name=奥田浩人
kn-aut-sei=奥田
kn-aut-mei=浩人
aut-affil-num=1
ORCID=
en-aut-name=KurodaSatoshi
en-aut-sei=Kuroda
en-aut-mei=Satoshi
kn-aut-name=黒田智
kn-aut-sei=黒田
kn-aut-mei=智
aut-affil-num=2
ORCID=
en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=濱野裕章
kn-aut-sei=濱野
kn-aut-mei=裕章
aut-affil-num=3
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=4
ORCID=
affil-num=1
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=2
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=3
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=4
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
END
start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=3
article-no=
start-page=227
end-page=235
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202406
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effect of Lipopolysaccharide on the Duration of Zolpidem-Induced Loss of Righting Reflex in Mice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Zolpidem, a non-benzodiazepine hypnotic, is primarily used to treat insomnia. In a previous study, pior treatment with non-benzodiazepine receptor agonists was associated with inflammation. The present study aimed to clarify the association between the effects of zolpidem and inflammation in mice treated with lipopolysaccharide (LPS), a known model of inflammation. We assessed the zolpidem-induced loss of righting reflex (LORR) duration 24 h after LPS treatment in mice. Additionally, the expressions of γ-aminobutyric acid (GABA)A receptor subunit and K+-Cl? cotransporter isoform 2 (KCC2) mRNA in the hippocampus and frontal cortex were examined in LPS-treated mice. Pretreatment with LPS was associated with significantly prolonged duration of zolpidem-induced LORR compared to control mice. This effect was significantly attenuated by administering bicuculline, a GABAA receptor antagonist, or flumazenil, a benzodiazepine receptor antagonist, in LPS-treated mice. Compared to controls, LPS-treated mice showed no significant change in the expression of GABAA receptor subunits in the hippocampus or frontal cortex. Bumetanide, an Na+-K+-2Cl? cotransporter isoform 1 blocker, attenuated the extended duration of zolpidem-induced LORR observed in LPS-treated mice. LPS significantly decreased Kcc2 mRNA expression in the hippocampus and the frontal cortex. These findings suggest that inflammation increases zolpidem-induced LORR, possibly through a reduction in KCC2 expression.
en-copyright=
kn-copyright=
en-aut-name=WadaYudai
en-aut-sei=Wada
en-aut-mei=Yudai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=UshioSoichiro
en-aut-sei=Ushio
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=KitamuraYoshihisa
en-aut-sei=Kitamura
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=SendoToshiaki
en-aut-sei=Sendo
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
affil-num=1
en-affil=Department of Clinical Pharmacy, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=2
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=3
en-affil=Department of Clinical Pharmacy, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=4
en-affil=Department of Clinical Pharmacy, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=5
en-affil=Department of Clinical Pharmacy, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=lipopolysaccharide
kn-keyword=lipopolysaccharide
en-keyword=zolpidem
kn-keyword=zolpidem
en-keyword=GABAA receptor
kn-keyword=GABAA receptor
en-keyword=K+-Cl? cotransporters
kn-keyword=K+-Cl? cotransporters
END
start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=
article-no=
start-page=1471602
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240904
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Ameliorating effect of chotosan and its active component, Uncaria hook, on lipopolysaccharide-induced anxiety-like behavior in mice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: In this study, we aimed to examine the effects of chotosan, a traditional Japanese botanical drug, and its active component, Uncaria hook, on anxiety-like behaviors induced by systemic inflammation in mice.
Methods: To induce systemic inflammation, the mice were treated with lipopolysaccharide (LPS), a bacterial endotoxin. Prior to LPS treatment, the mice were administered chotosan or Uncaria hook orally each day for 14 days. Anxiety-like behavior of the mice was evaluated using the light-dark test 24 h after LPS treatment.
Results: Repeated administration of chotosan prevented anxiety-like behavior in both normal and LPS-treated mice. Similarly, administration of Uncaria hook suppressed LPS-induced anxiety-like behavior in mice. Furthermore, treatment with tandospirone, a 5-HT1A receptor agonist, alleviated anxiety-like behavior in mice, whereas treatment with DOI, a 5-HT2A receptor agonist, enhanced anxiety-like behavior in mice. LPS treatment significantly increased serotonin (5-HT)(2A) receptor mRNA expression in the frontal cortex, whereas 5-HT1A receptor mRNA expression remained unchanged in the hippocampus. Notably, chotosan significantly suppressed the mRNA expression of 5-HT2A receptor.
Discussion: These findings indicate that chotosan exerts anxiolytic-like effects in the context of inflammation-induced anxiety, potentially mediated by the inhibition of 5-HT2A receptor hyperfunction in LPS-treated mice. Consequently, we postulate that chotosan may be effective in managing inflammation-induced anxiety-like behaviors.
en-copyright=
kn-copyright=
en-aut-name=OkawaYasumasa
en-aut-sei=Okawa
en-aut-mei=Yasumasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=UshioSoichiro
en-aut-sei=Ushio
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=IzushiYasuhisa
en-aut-sei=Izushi
en-aut-mei=Yasuhisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=KitamuraYoshihisa
en-aut-sei=Kitamura
en-aut-mei=Yoshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=SendoToshiaki
en-aut-sei=Sendo
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
affil-num=1
en-affil=Department of Clinical Pharmacy, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=2
en-affil=Department of Clinical Pharmacy, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=3
en-affil=Department of Pharmacotherapy, School of Pharmacy, Shujitsu University
kn-affil=
affil-num=4
en-affil=Department of Pharmacotherapy, School of Pharmacy, Shujitsu University
kn-affil=
affil-num=5
en-affil=Department of Clinical Pharmacy, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=6
en-affil=Department of Clinical Pharmacy, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=anxiolytic
kn-keyword=anxiolytic
en-keyword=chotosan
kn-keyword=chotosan
en-keyword=inflammation
kn-keyword=inflammation
en-keyword=serotonin receptor
kn-keyword=serotonin receptor
en-keyword=Uncaria hook
kn-keyword=Uncaria hook
END
start-ver=1.4
cd-journal=joma
no-vol=47
cd-vols=
no-issue=3
article-no=
start-page=237
end-page=249
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20231222
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=International Trends in Adverse Drug Event-Related Mortality from 2001 to 2019: An Analysis of the World Health Organization Mortality Database from 54 Countries
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background and Objective
Adverse drug events (ADEs) are becoming a significant public health issue. However, reports on ADE-related mortality are limited to national-level evaluations. Therefore, we aimed to reveal overall trends in ADE-related mortality across the 21st century on an international level.
Methods
This observational study analysed long-term trends in ADE-related mortality rates from 2001 to 2019 using the World Health Organization Mortality Database. The rates were analysed according to sex, age and region. North America, Latin America and the Caribbean, Western Europe, Eastern Europe and Western Pacific regions were assessed. Fifty-four countries were included with four-character International Statistical Classification of Disease and Related Health Problems, Tenth Revision codes in the database, population data in the World Population Prospects 2019 report, mortality data in more than half of the study period, and high-quality or medium-quality death registration data. A locally weighted regression curve was used to show international trends in age-standardised rates.
Results
The global ADE-related mortality rate per 100,000 population increased from 2.05 (95% confidence interval 0.92?3.18) in 2001 to 6.86 (95% confidence interval 5.76?7.95) in 2019. Mortality rates were higher among men than among women, especially in those aged 20?50 years. The population aged ??75 years had higher ADE-related mortality rates than the younger population. North America had the highest mortality rate among the five regions. The global ADE-related mortality rate increased by approximately 3.3-fold from 2001 to 2019.
Conclusions
The burden of ADEs has increased internationally with rising mortality rates. Establishing pharmacovigilance systems can facilitate efforts to reduce ADE-related mortality rates globally.
en-copyright=
kn-copyright=
en-aut-name=KoyamaToshihiro
en-aut-sei=Koyama
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=IinumaShunya
en-aut-sei=Iinuma
en-aut-mei=Shunya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=YamamotoMichio
en-aut-sei=Yamamoto
en-aut-mei=Michio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=NiimuraTakahiro
en-aut-sei=Niimura
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=OsakiYuka
en-aut-sei=Osaki
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=NishimuraSayoko
en-aut-sei=Nishimura
en-aut-mei=Sayoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=HaradaKo
en-aut-sei=Harada
en-aut-mei=Ko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
affil-num=1
en-affil=Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=2
en-affil=Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=3
en-affil=Graduate School of Human Sciences, Osaka University, Osaka, Japan RIKEN Center for Advanced Intelligence Project,
kn-affil=
affil-num=4
en-affil=Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School
kn-affil=
affil-num=5
en-affil=Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=6
en-affil=Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=7
en-affil=Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel
kn-affil=
affil-num=8
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=9
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=
END
start-ver=1.4
cd-journal=joma
no-vol=136
cd-vols=
no-issue=3
article-no=
start-page=135
end-page=138
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241202
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Drug interaction (61. Drug interactions of cancer cachexia therapeutics)
kn-title=薬物相互作用（61―がん悪液質治療薬の相互作用）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
en-aut-name=KawakamiEiji
en-aut-sei=Kawakami
en-aut-mei=Eiji
kn-aut-name=川上英治
kn-aut-sei=川上
kn-aut-mei=英治
aut-affil-num=1
ORCID=
en-aut-name=OkudaHiroto
en-aut-sei=Okuda
en-aut-mei=Hiroto
kn-aut-name=奥田浩人
kn-aut-sei=奥田
kn-aut-mei=浩人
aut-affil-num=2
ORCID=
en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=濱野裕章
kn-aut-sei=濱野
kn-aut-mei=裕章
aut-affil-num=3
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=4
ORCID=
affil-num=1
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=2
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=3
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=4
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
END
start-ver=1.4
cd-journal=joma
no-vol=46
cd-vols=
no-issue=2
article-no=
start-page=536
end-page=541
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240119
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Palbociclib and abemaciclib are cyclin-dependent kinase (CDK) 4/6 inhibitors currently used to treat breast cancer. Although their therapeutic efficacies are considered comparable, differences in adverse event (AE) profiles of the two drugs remain unclear.
Aim We analysed two real-world databases, the World Health Organization’s VigiBase and the Food and Drug Administration Adverse Event Reporting System (FAERS), to identify differences in AE profiles of palbociclib and abemaciclib.
Method Data of patients with breast cancer receiving palbociclib or abemaciclib recorded until December 2022 were extracted from the VigiBase and FAERS databases. In total, 200 types of AEs were analysed. The reporting odds ratios were calculated using a disproportionality analysis.
Results Cytopenia was frequently reported in patients receiving palbociclib, whereas interstitial lung disease and diarrhoea were frequently reported in those receiving abemaciclib. Moreover, psychiatric and nervous system disorders were more common in the palbociclib group, whereas renal and urinary disorders were more common in the abemaciclib group.
Conclusion This study is the first to show comprehensively the disparities in the AE profiles of palbociclib and abemaciclib. The findings highlight the importance of considering these differences when selecting a suitable CDK4/6 inhibitor to ensure safe and favourable outcomes for patients with breast cancer.
en-copyright=
kn-copyright=
en-aut-name=TakedaTatsuaki
en-aut-sei=Takeda
en-aut-mei=Tatsuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=SugimotoShiho
en-aut-sei=Sugimoto
en-aut-mei=Shiho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=MatsumotoJun
en-aut-sei=Matsumoto
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=IwataNaohiro
en-aut-sei=Iwata
en-aut-mei=Naohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=NakamotoAkihiko
en-aut-sei=Nakamoto
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=OzakiAya Fukuma
en-aut-sei=Ozaki
en-aut-mei=Aya Fukuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=AriyoshiNoritaka
en-aut-sei=Ariyoshi
en-aut-mei=Noritaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=
affil-num=1
en-affil=Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=2
en-affil=Department of Personalized Medicine and Preventive Healthcare Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=3
en-affil=Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=4
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=5
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=6
en-affil=Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California
kn-affil=
affil-num=7
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=8
en-affil=Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=9
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
en-keyword=Abemaciclib
kn-keyword=Abemaciclib
en-keyword=Adverse event
kn-keyword=Adverse event
en-keyword=Breast cancer
kn-keyword=Breast cancer
en-keyword=Cyclin-dependent kinase 4/6 inhibitor
kn-keyword=Cyclin-dependent kinase 4/6 inhibitor
en-keyword=Palbociclib
kn-keyword=Palbociclib
END
start-ver=1.4
cd-journal=joma
no-vol=134
cd-vols=
no-issue=1
article-no=
start-page=43
end-page=47
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=20220401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Drug interaction (53. Interaction of traditional Japanese herbal medicines in chemotherapy)
kn-title=薬物相互作用（53―がん領域に用いる漢方薬の相互作用）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
en-aut-name=IwataNaohiro
en-aut-sei=Iwata
en-aut-mei=Naohiro
kn-aut-name=岩田直大
kn-aut-sei=岩田
kn-aut-mei=直大
aut-affil-num=1
ORCID=
en-aut-name=EsumiSatoru
en-aut-sei=Esumi
en-aut-mei=Satoru
kn-aut-name=江角悟
kn-aut-sei=江角
kn-aut-mei=悟
aut-affil-num=2
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=3
ORCID=
affil-num=1
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=2
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=3
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
END
start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=1
article-no=
start-page=51
end-page=58
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202502
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Photoinitiators Induce Histamine Production in Human Mast Cells
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Photoinitiators are used in the manufacture of many daily products, and may produce harmful effects due to their cytotoxicity. They have also been detected in human serum. Here, we investigated the histamine-producing effects in HMC-1 cells and the inflammatory cytokine release effects in RAW264 cells for four photoinitiators: 1-hydroxycyclohexyl phenyl ketone; 2-isopropylthioxanthone; methyl 2-benzoylbenzoate; and 2-methyl-4´-(methylthio)-2-morpholinopropiophenone. All four promoted histamine production in HMC-1 cells; however, they did not significantly affect the release of inflammatory cytokines in RAW264 cells. These findings suggest that these four photoinitiators induce inflammatory cytokine-independent histamine production, potentially contributing to histamine-mediated chronic inflammation in vitro.
en-copyright=
kn-copyright=
en-aut-name=MiuraTaro
en-aut-sei=Miura
en-aut-mei=Taro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=KawasakiYoichi
en-aut-sei=Kawasaki
en-aut-mei=Yoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=SendoToshiaki
en-aut-sei=Sendo
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
affil-num=1
en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=2
en-affil=Laboratory of Clinical Pharmacology and Therapeutics, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University
kn-affil=
affil-num=3
en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=4
en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
affil-num=5
en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=photoinitiator
kn-keyword=photoinitiator
en-keyword=ink
kn-keyword=ink
en-keyword=injection
kn-keyword=injection
en-keyword=histamine
kn-keyword=histamine
en-keyword=inflammation
kn-keyword=inflammation
END
start-ver=1.4
cd-journal=joma
no-vol=137
cd-vols=
no-issue=1
article-no=
start-page=30
end-page=32
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250401
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Drug interaction (62. Drug interactions of potassium absorption agents)
kn-title=薬物相互作用（62―カリウム吸着薬の薬物相互作用）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=
en-aut-name=ArikiSaori
en-aut-sei=Ariki
en-aut-mei=Saori
kn-aut-name=有木沙織
kn-aut-sei=有木
kn-aut-mei=沙織
aut-affil-num=1
ORCID=
en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=濱野裕章
kn-aut-sei=濱野
kn-aut-mei=裕章
aut-affil-num=2
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=座間味義人
kn-aut-sei=座間味
kn-aut-mei=義人
aut-affil-num=3
ORCID=
affil-num=1
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=2
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
affil-num=3
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=岡山大学病院 薬剤部
END
start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250508
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Comprehensive analysis of adverse event profile changes with pertuzumab addition to trastuzumab‐based breast cancer therapy: Disproportionality analysis using VigiBase
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aims: Pertuzumab is used in combination with trastuzumab-based therapy for HER2-positive breast cancer. However, real-world safety information on pertuzumab remains limited. This study assessed the safety of adding pertuzumab to trastuzumab-based therapy for HER2-positive breast cancer using real-world data.
Methods: VigiBase, the World Health Organization's global database of adverse events (AEs), containing reports from November 1967 to December 2023, was used. Signals for pertuzumab-associated AEs in breast cancer cases were detected using the reporting odds ratio (ROR).
Results: Signals of trastuzumab plus pertuzumab relative to trastuzumab alone were detected in gastrointestinal disorders (ROR: 1.45, 95% confidence interval: 1.26?1.67), including diarrhoea (3.49, 2.83?4.30); infections and infestations (1.54, 1.24?1.91); and skin and subcutaneous tissue disorders (ROR: 1.63, 1.40?1.90), including pruritus (1.96, 1.51?2.55) and rash (1.63, 1.20?2.23). Further, signals of trastuzumab plus docetaxel plus pertuzumab relative to those of trastuzumab plus docetaxel were detected in gastrointestinal disorders (1.63, 1.38?1.93), including nausea (1.72, 1.24?2.39) and vomiting (1.48, 1.01?2.17), and in nervous system disorders (1.50, 1.20?1.87), including paraesthesia (2.60, 1.33?5.08) and peripheral sensory neuropathy (5.94, 1.79?19.71). The frequency of AEs causing or prolonging hospitalization was increased with trastuzumab plus pertuzumab compared to that with trastuzumab alone (1.18, 1.00?1.38).
Conclusions: AE profiles after the addition of pertuzumab to trastuzumab-based therapy were comprehensively identified. The findings in this study highlight the importance of considering these AEs when selecting pertuzumab combination therapy to ensure the safety of patients with breast cancer.
en-copyright=
kn-copyright=
en-aut-name=TakedaTatsuaki
en-aut-sei=Takeda
en-aut-mei=Tatsuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=
en-aut-name=MatsumotoJun
en-aut-sei=Matsumoto
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=
en-aut-name=SakaiTomonori
en-aut-sei=Sakai
en-aut-mei=Tomonori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=
en-aut-name=IwataNaohiro
en-aut-sei=Iwata
en-aut-mei=Naohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=
en-aut-name=HamanoHirofumi
en-aut-sei=Hamano
en-aut-mei=Hirofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=
en-aut-name=KoyamaToshihiro
en-aut-sei=Koyama
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=
en-aut-name=AriyoshiNoritaka
en-aut-sei=Ariyoshi
en-aut-mei=Noritaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=
en-aut-name=ZamamiYoshito
en-aut-sei=Zamami
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=
affil-num=1
en-affil=Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=2
en-affil=Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=3
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=4
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=5
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
affil-num=6
en-affil=Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=7
en-affil=Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Okayama University
kn-affil=
affil-num=8
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=
en-keyword=adverse event
kn-keyword=adverse event
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=pertuzumab
kn-keyword=pertuzumab
en-keyword=trastuzumab
kn-keyword=trastuzumab
en-keyword=VigiBase
kn-keyword=VigiBase
END